Envíe este artículo por correo electrónico (Inicie sesión)
Enviar un correo electrónico al autor/a (Inicie sesión) Open Journal Systems
Incompatibilidad ABO en el trasplante de células progenitoras hematopoyéticas y sus complicaciones / ABO incompatibility and complications in hematopoietic stem cell transplantation
Resumen
Resumen
Introducción: los trasplantes de células progenitoras hematopoyéticas (TCPH) se pueden hacer independientemente de la compatibilidad de grupo sanguíneo ABO entre donador y receptor. La incompatibilidad ABO (IABO) en los TCPH puede presentar complicaciones, como aplasia pura de serie roja (APSR), o síndrome de linfocito pasajero. El impacto de la IABO en la enfermedad del injerto en contra del huésped y la mortalidad relacionada al trasplante es controversial por la heterogeneidad de procedimientos que se hacen en los distintos centros de trasplante.
Objetivo: determinar la prevalencia de la IABO y sus complicaciones en los pacientes trasplantados en una unidad de trasplante de progenitores hematopoyéticos.
Material y métodos: se hizo un estudio tipo observacional, descriptivo, en pacientes sometidos a TCPH de enero de 2014 a enero de 2020. Se incluyeron todos los pacientes trasplantados. Las variables cualitativas se analizaron con chi cuadrada y para las variables cuantitativas se usó la prueba de Wilcoxon y t de Student. Una p < 0.05 fue significativa.
Resultados: se analizaron 124 pacientes sometidos a TCPH y 31 de ellos presentaron IABO, con una prevalencia puntual de 24.4%; entre ellos, 54% presentaron incompatibilidad mayor, 32% incompatibilidad menor y 13% incompatibilidad bidireccional. Se reportaron tres casos de APSR. No hubo diferencias en la supervivencia global a un año en ambos grupos.
Conclusiones: la IABO y sus complicaciones no se relacionaron con aumento en la mortalidad. Se requieren estudios prospectivos aleatorizados para definir el papel de la IABO con el pronóstico del trasplante.
Abstract
Background: Hematopoietic stem cell transplants (HSCT) can be performed regardless of the ABO group compatibility between donor and recipient. ABO incompatibility in HSCT is related to pure red cell aplasia (PRCA), or passenger lymphocyte syndrome. The impact of ABO incompatibility on graft-versus-host disease and transplant-related mortality is controversial due to the heterogeneity of procedures carried out in different transplant centers.
Objective: To determine the prevalence of ABO incompatibility and its complications in a hematopoietic stem transplant unit.
Material and methods: An observational, retrospective study was carried out in patients undergoing HSCT from January 2014 to January 2020. All trasplant patients were included. Qualitative variables were analyzed using chi-squared test, and Wilcoxon and Student's t tests were used for quantitative variables. A p < 0.05 was considered significant.
Results: 124 patients undergoing HSCT were analyzed, out of which 31 had ABO incompatibility, with a punctual prevalence of 24.4%; among them, 54% presented with major incompatibility, 32% minor incompatibility and 13% bidirectional incompatibility. Three cases of PRCA were reported. There were no differences in survival at one year in both groups.
Conclusions: The ABO incompatibility ant its complications were not related to the increase in mortality. Randomized prospective studies are required to define the role of ABO incompatibility in HSCT prognosis.
Palabras clave
Texto completo:
PDFReferencias
Gyurkocza B, Rezvani A, Storb R. Allogeneic hematopoietic cell transplantation: the state of the art. Expert Rev of Hematol. 2010;3(3):285-99. doi: 10.1586/ehm.10.21.
Henig I, Zuckerman T. Hematopoietic Stem Cell Transplantation—50 Years of Evolution and Future Perspectives. Rambam Maimonides Med J. 2014;5(4):e0028. doi: 10.5041/RMMJ.10162.
Rummel SK, Ellsworth RE. The role of the histoblood ABO group in cancer. Future Sci OA. 2016;2(2): FSO107. doi: 10.4155/fsoa-2015-0012.
Canizalez A, Campos A, Castro J, López M, Andrade F, Cruz C et al. Blood Groups Distribution and Gene Diversity of the ABO and Rh (D) Loci in the Mexican Population. BioMed Res Intl. 2018;2018:1925619. doi: 10.1155/2018/1925619.
Yamamoto F. Review: ABO blood groups system-ABH oligosaccharide antigens, anti-A and anti-B, A and B glycosyltransferases, and ABO genes. Immunohematology. 2004;20(1):3-22.
Kominato Y, Hata Y, Matsui K, Takizawa H, Tsukada J. Nakajima T, et al. Transcriptional regulation of the human ABO histo-blood group genes is dependent on the N box upstream of the proximal promoter. Transfusion. 2004;44(12):1741-9. doi: 10.1111/j.0041-1132.2004.04028.x.
Adkins B, Booth G, Vasu S. Transfusion support for stem cell transplant recipients. Semin Hematol. 2020;57(2):51-6. doi: 10.1053/j.seminhematol.2020.07.001.
Rowley S, Donato M, Bhattacharyya P. Red blood cell-incompatible allogeneic hematopoietic progenitor cell transplantation. Bone Marrow Transplant. 2011;46(9):1167-85. doi: 10.1038/bmt.2011.135.
Kimura F, Sato K, Kobayashi S, Ikeda T, Sao H, Okamoto S et al. Impact of AB0-blood group incompatibility on the outcome of recipients of bone marrow transplants from unrelated donors in the Japan Marrow Donor Program. Haematologica. 2008;93(11):1686-93. doi: 10.3324/haematol.12933.
Staley E, Schwartz J, Pham H. An update on ABO incompatible hematopoietic progenitor cell transplantation. Transfus Apher Sci. 2016;54(3):337-44. doi: 10.1016/j.transci.2016.05.010.
Means R. Pure red cell aplasia. Blood. 2016;128(21):2504-9. doi: 10.1182/sangre-2016-05-717140.
Roychowdhury FD, Linker CA. Pure red cell aplasia complicating an ABO-compatible allogeneic bone marrow transplantation, treated successfully with antithymocyte globulin. Bone Marrow Transplant.1995;16(3):471-2.
Franchini M, Liumbruno G. ABO blood group: old dogma, new perspectives. Clin Chem Lab Med. 2013;51(8):1545-53. doi: 10.1515/cclm-2013-0168.
Audet M, Panaro F, Piardi T, Huang P, Cag M, Cinqualbre J et al. Passenger Lymphocyte Syndrome and Liver Transplantation. Clin Dev Immunol. 2008;2008: 715769. doi: 10.1155/2008/715769.
Peck JR, Elkhammas EA, Li F, Stanich PP, Latchana N, Black S et al. Passenger lymphocyte syndrome: a forgotten cause of postliver transplant jaundice and anemia. Exp Clin Transplant. 2015;13(2):200-2. doi: 10.6002/ect.2013.0239.
Teshigawara-Tanabe H, Hagihara M, Matsumura A, Takahashi H, Nakajima Y, Miyazaki T et al. Passenger lymphocyte syndrome after ABO-incompatible allogeneic hematopoietic stem cell transplantation; dynamics of ABO allo-antibody and blood type conversion. Hematology. 2021;26(1):835-9. doi: 10.1080/16078454.2021.1986654.
Shokrgozar N, Tamaddon G. ABO Blood Grouping Mismatch in Hematopoietic Stem Cell Transplantation and Clinical Guides. Int J Hematol Oncol Stem Cell Res. 2018;12(4):322-8.
Moosavi M, Duncan A, Stowell S, Roback J, Sullivan H. Passenger Lymphocyte Syndrome; a Review of the Diagnosis, Treatment, and Proposed Detection Protocol. Transfus Med Rev. 2020;34(3):178-87. doi: 10.1016/j.tmrv.2020.06.004.
Ataca Atilla P, Akkus E, Atilla E, Gokmen N, Civriz Bozdag S, Kocak Toprak S et al. Effects of ABO incompatibility in allogeneic hematopoietic stem cell transplantation. Transfus Clin Bio. 2020;27(3):115-21. doi: 10.1016/j.tracli.2020.06.008.
Worel N. ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation. Transfus Med Hemother. 2016;43(1):3-12. doi: 10.1159/000441507.
Zhu P, Wu Y, Cui D, Shi J, Yu J, Zhao Y et al. Prevalence of Pure Red Cell Aplasia Following Major ABO-Incompatible Hematopoietic Stem Cell Transplantation. Front Immunol. 2022;13:829670. doi: 10.3389/fimmu.2022.829670.
Watz E, Remberger M, Ringden O, Lundahl J, Ljungman P, Mattsson J et al. Analysis of Donor and Recipient ABO Incompatibility and Antibody-Associated Complications after Allogeneic Stem Cell Transplantation with Reduced-Intensity Conditioning. Biol Blood Marrow Transplant. 2014;20(2):264-71. doi: 10.1016/j.bbmt.2013.11.011.
Blin N, Traineau R, Houssin S, Peffault de Latour R, Petropoulou A, Robin M et al. Impact of Donor-Recipient Major ABO Mismatch on Allogeneic Transplantation Outcome According to Stem Cell Source. Biol Blood Marrow Transplant. 2010;16(9):1315-23. doi: 10.1016/j.bbmt.2010.03.021.
Logan A, Wang Z, Alimoghaddam K, Wong R, Lai T, Negrin R et al. ABO Mismatch Is Associated with Increased Nonrelapse Mortality after Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2015;21(4):746-54. doi: 10.1016/j.bbmt.2014.12.036.
Booth G, Gehrie E, Bolan C, Savani B. Clinical guide to ABO-incompatible allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2013;19(8):1152-8. doi: 10.1016/j.bbmt.2013.03.018.
Migdady Y, Pang Y, Kalsi S, Childs R, Arai S. Post–hematopoietic stem cell transplantation immune-mediated anemia: a literature review and novel therapeutics. Blood Adv. 2022;6(8):2707-21. doi: 10.1182/bloodadvances.2021006279.
Gutiérrez C, Gómez-de León A, Alatorre J, Cantú O, González O, Jaime J et al. Allogeneic peripheral blood stem cell transplantation using reduced-intensity conditioning in an outpatient setting in ABO-incompatible patients: are survival and graft-versus-host disease different? Transfusion. 2014;54(5):1269-77. doi: 10.1111/trf.12466.
Benjamin RJ, McGurk S, Ralston MS, Churchill WH, Antin JH. ABO incompatibility as an adverse risk factor for survival after allogeneic bone marrow transplantation. Transfusion. 1999;39(2):179-87. doi: 10.1046/j.1537-2995.1999.39299154733.x.
Stussi G, Halter J, Bucheli E, Valli PV, Seebach L, Gmür J, et al. Prevention of pure red cell aplasia after major or bidirectional ABO blood group incompatible hematopoietic stem cell transplantation by pretransplant reduction of host anti-donor isoagglutinins. Haematologica. 2009;94(2):239-48. doi: 10.3324/haematol.13356.
Mehta J, Powles R, Sirohi B, Treleaven J, Kulkarni S, Saso R, et al. Does donor-recipient ABO incompatibility protect against relapse after allogeneic bone marrow transplantation in first remission acute myeloid leukemia? Bone Marrow Transplant. 2002;29(10):853-9. doi: 10.1038/sj.bmt.1703545.
Enlaces refback
- No hay ningún enlace refback.